TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

TScan Therapeutics (TCRX) announced participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference scheduled for May 24, 2022, at 7:00 a.m. ET. This event will focus on TCR engineered T cell therapies for cancer treatment. A live webcast will be accessible through the company’s website, and a replay will be available for 30 days afterward. The company specializes in TCR-T therapies targeting hematologic malignancies and solid tumors, leveraging its ImmunoBank of therapeutic TCRs.

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference that will be available for viewing on Tuesday, May 24, 2022, at 7:00 a.m. ET.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead leukemia TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s bank of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with various types of solid tumors.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

FAQ

What event will TScan Therapeutics participate in on May 24, 2022?

TScan Therapeutics will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET.

Where can I watch the TScan Therapeutics fireside chat?

The fireside chat can be viewed on TScan Therapeutics' website under the 'Events and Presentations' section.

How long will the webcast of the TScan Therapeutics chat be available?

An archived replay of the TScan Therapeutics fireside chat will be available on the company's website for 30 days following the event.

What is TScan Therapeutics focused on developing?

TScan Therapeutics focuses on developing T-cell receptor (TCR) engineered T cell therapies for cancer treatment.

What are the lead therapies being developed by TScan Therapeutics?

TScan's lead therapies are TSC-100 and TSC-101, which target hematologic malignancies.